Healthy Longevity ScienceExplore the questions behind healthy longevity. Understand the evidence, its possibilities and its limits.
12 articles
PeptidesInsulin and semaglutide have established benefits in defined conditions. BPC-157, TB-500 and MOTS-c have much earlier evidence for healing or physical performance. This guide compares the actual human findings, explains why similar peptide names can hide different treatments, and shows how Healthy Longevity Clinic weighs disease prevention, recovery and function against risk.
PeptidesThe seven-amino-acid fragment called TB-500 has no demonstrated healing benefit in people. Human eye and heart studies tested different preparations. One eye trial enrolled 18 people and missed its main goal; a later trial also missed it. The distinction matters: a promising result for one molecule cannot establish what another does.
PeptidesMK-677, CJC-1295, ipamorelin, sermorelin and capromorelin differ in their evidence for strength, mobility and cognition. In a 65-person trial, MK-677 increased fat-free mass without improving strength or function, while blood glucose rose. Other studies found narrower benefits. Healthy Longevity Clinic examines which results could support independence, and where hormonal changes leave the clinical question unanswered.
Removing damaged cells helped some mice, but worsened disease in other experiments. FOXO4-DRI’s 2017 results opened a research path, not a proven anti-aging treatment. Cleara is developing distinct candidates for cancer and reports preclinical progress. The central question is which cells can be removed without harming the tissue they live in.
PeptidesThe larger LL-37 leg-ulcer trial found no overall healing benefit: confirmed closure was about 25% with or without the peptide. Smaller studies and laboratory work remain interesting, but LL-37 also affects human cells. Maxwell Biosciences’ engineered peptoids take a different chemical approach; their reported milestones are progress toward testing, not proof of patient benefit.
PeptidesBPC-157 has not convincingly shown that it heals injuries in people. A September 2026 analysis found 279 reports of improvement among 1,039 users—but 685 had no recorded outcome. Small human studies offer clues, not a reliable benefit or safety estimate. A planned 120-person hamstring trial could provide a stronger test.
PeptidesMOTS-c can rise during exercise, but taking it has not been shown to reproduce exercise’s benefits. A 2021 study measured the peptide in ten young men who cycled; it did not treat them. A planned 120-person treatment trial could test whether MOTS-c improves the body’s response to insulin.
PeptidesThe often-cited study of 266 older people did not test Epitalon. It tested gland extracts, including Epithalamin. Epitalon itself has laboratory telomere findings and limited human reports, but no demonstrated healthy-aging or sleep benefit. The similar names hide the most important distinction.
PeptidesThymosin alpha-1 has a substantial human research record, but that record does not establish healthy-aging benefit. In the 2025 TESTS sepsis trial, 28-day mortality was 23.4% with treatment and 24.1% with placebo. Some vaccine studies found immune-marker changes. Whether generally healthy older adults get fewer serious infections remains unanswered.
PeptidesBPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon were evaluated for specific pharmacy-compounding uses at the July 23–24, 2026 FDA meeting. The meeting did not approve them as medicines. This guide explains the separate decisions on compounding, drug approval and GHK-Cu administration—and why US changes do not authorize a product in the EU or Czechia.
Peptides“Research use only” does not mean a product is suitable for treatment. In a small 2024 study, three products bought online as semaglutide contained 29%–39% more active drug than their labels stated; one also had elevated bacterial toxins. Those findings concern the tested products, but illustrate why identity, amount, contamination, and clinical benefit need separate answers.
PeptidesBPC-157 is prohibited in and out of competition under the 2026 World Anti-Doping Agency (WADA) list. That matters for amateurs as well as professionals when their sport applies those rules. A prescription does not create an exemption, and the US Anti-Doping Agency (USADA) calls a BPC-157 exemption unlikely, not impossible. Start with your governing authority, the exact substance, and the medical reason for treatment.